MyMD Pharmaceuticals Enrolls First Client in Phase 2 Medical Test of MYMD-1 as a Therapy for Delaying Aging and Increasing Healthy And Balanced Lifespan

MyMD Pharmaceuticals, Inc. MYMD Stock (” MyMD” or “the Business”), a scientific stage pharmaceutical firm devoted to prolonging healthy life-span, today introduced that the initial client has been enrolled in the Company’s Phase 2 medical trial of lead candidate MYMD-1, a dental immune regulatory authority drug, as a therapy for delaying aging and increasing healthy life-span.

The primary endpoint for the Phase 2 double-blind, placebo-controlled professional trial is to achieve a reduction in the circulating degrees of (TNF-α), tumor necrosis aspect receptor I (TNFRI) as well as IL-6. TNF-α and also IL-6 are the healthy proteins in the body that create inflammation and also assist turn on the procedure of aging. The second measures of the test will be the safety and security, tolerability, as well as pharmacokinetics in this populace of clients.

” In a Phase 1 scientific trial of MYMD-1, we showed the medication’s statistically substantial effectiveness in lowering degrees of TNF-α, a principal in causing pathological aging, in the blood. The FDA has actually approved TNF-α reduction as the key endpoint for our Stage 2 research study, which our company believe positions us well for an effective Stage 2 result,” claimed Chris Chapman, M.D., Head Of State, Director and also Principal Medical Police Officer of MyMD. “The initiation of individual registration in this research study advances our goal to reduce the aging procedure, avoid loss of muscle cells in aging, restriction frailty, and also extend healthy and balanced lifespan.”

MyMD has specified that there are no FDA-approved medicines for treating aging conditions and also expanding healthy and balanced life-span humans, a market anticipated to be at the very least $600 billion by 20251 according to a significant investment bank. TNF-α blockers are the most prescribed drugs by income, an international market of around $40 billion each year,2 and, according to Nature Aging journal,3 a slowdown in maturing that would certainly boost life expectancy by one year deserves $38 trillion and by one decade deserves $367 trillion.

Along with aging, MYMD-1’s unique action in controling the body immune system and dealing with chronic swelling is being created for the therapy of autoimmune condition, including rheumatoid arthritis (RA), numerous sclerosis (MS), diabetes mellitus, and also inflammatory digestive tract condition.

” We intend to begin creating procedures for a Stage 2 pilot research of MYMD-1 for rheumatoid arthritis early this year,” Dr. Chapman kept in mind. “The climbing frequency of rheumatoid joint inflammation as well as other autoimmune as well as inflammatory diseases are driving demand for TNF inhibitors like MYMD-1, as well as we believe our by mouth administered medication with very reduced poisoning would certainly be turbulent to the $60 billion market for RA if approved by the FDA for this indication.”

Rheumatoid joint inflammation affects around 40 million people around the world.4.

Concerning MYMD-1.

Originally developed for autoimmune conditions, MYMD-1’s key function is to slow down the aging process, avoid sarcopenia and frailty, and also prolong healthy and balanced life expectancy. Since it can go across the blood-brain barrier as well as gain access to the central nerve system (CNS), MYMD-1 is likewise placed to be a possible therapy for brain-related problems. Its system of action and also effectiveness in illness including multiple sclerosis (MS) as well as thyroiditis have been researched through collaborations with numerous academic organizations. MYMD-1 is additionally revealing guarantee in pre-clinical research studies as a possible treatment for post- COVID-19 issues and as an anti-fibrotic as well as anti-proliferation healing.

MYMD-1 has revealed effectiveness in pre-clinical research studies in managing the immune system by carrying out as a discerning prevention of tumor necrosis factor-alpha (TNF-α), a chauffeur of chronic swelling. Unlike other therapies, MYMD-1 has been displayed in these pre-clinical research studies to selectively block TNF-α when it becomes overactivated in autoimmune illness and also cytokine storms, but not obstruct it from doing its normal job of being a first -responder to any kind of routine kind of moderate infection. MYMD-1’s convenience of dental application is an additional differentiator compared to currently available TNF-α blockers, every one of which require distribution by shot or infusion. No approved TNF inhibitor has ever been dosed by mouth. Additionally, the medicine is not immunosuppressive as well as has actually not been shown to trigger the major negative effects usual with traditional therapies that treat swelling.

Regarding MyMD Pharmaceuticals, Inc

. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a professional stage pharmaceutical company committed to prolonging healthy life expectancy, is concentrated on developing two novel restorative platforms that deal with the sources of disease instead of only dealing with the signs. MYMD-1 is a drug system based upon a professional phase small particle that regulates the body immune system to manage TNF-α, which drives persistent inflammation, and various other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, boost durability, and deal with autoimmune diseases and also COVID-19- linked anxiety. The Firm’s 2nd medicine system, Supera-CBD, is being developed to treat persistent pain, dependency and epilepsy. Supera-CBD is a novel synthetic by-product of cannabidiol (CBD) as well as is being established to deal with and also surpass the swiftly growing CBD market, which includes both FDA approved medicines and also CBD products not presently regulated as medicines. To learn more, browse through www.mymd.com.